Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme.
Adelphi Migraine Disease Specific Programme
Japan
Migraine
Quality of life
Retrospective study
Treatment satisfaction
Work productivity
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
08 Jul 2020
08 Jul 2020
Historique:
received:
25
11
2019
accepted:
29
06
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
28
10
2020
Statut:
epublish
Résumé
Real-world data on sufficient/insufficient response, and predictors of insufficient response, to acute treatments for migraine are limited in Japan. This study aimed to identify factors associated with insufficient response to acute treatment of migraine by exploring significant differences between people with migraine who sufficiently/insufficiently respond to prescribed acute treatment in Japan. This was a retrospective analysis of 2014 Adelphi Migraine Disease Specific Programme cross-sectional survey data collected from physicians and their consulting adult patients with migraine in Japan. Insufficient responders to prescribed acute treatment were patients who achieved headache pain freedom within 2 h of acute treatment in no more than three of their last five migraine attacks. Factors associated with insufficient response to prescribed acute migraine treatment were identified using backward logistic regression. Overall, 227/538 (42.2%) patients were classified as insufficient responders to prescribed acute migraine treatment. Significantly more insufficient responders than sufficient responders had consulted a neurologist or a migraine/headache specialist, and had chronic migraine or medication-overuse or tension-type headaches (p < 0.05). More insufficient responders than sufficient responders reported taking acute treatment when/after the pain started (77.0 vs. 68.9%) than at first sign of migraine (p < 0.05). Compared with sufficient responders, insufficient responders reported a significantly higher mean ± standard deviation (SD) Migraine Disability Assessment total score (12.7 ± 23.3 vs. 5.8 ± 10.4, p < 0.001) and lower quality of life (EuroQol-5 Dimensions utility score 0.847 ± 0.19 vs. 0.883 ± 0.16, p = 0.024). Factors significantly associated with insufficient response to acute treatment included seeing a neurologist versus an internist (odds ratio [OR] 1.93; 95% confidence interval [CI] 1.29-2.88; p = 0.002), taking acute medication when/after pain started versus at first sign of migraine (OR 1.65; 95% CI 1.05-2.60; p = 0.030), a higher MIDAS total score (OR 1.04; 95% CI 1.02-1.06; p < 0.001), and presence of comorbid cardiovascular disease (OR 0.53; 95% CI 0.28-0.98; p = 0.044). Many people with migraine in Japan struggle to adequately treat migraine attacks with prescribed acute medication and exhibit high levels of unmet need for acute treatment. Optimized management strategies utilizing existing therapeutic options as well as additional effective therapeutic options for migraine are required to improve symptoms and quality of life.
Sections du résumé
BACKGROUND
BACKGROUND
Real-world data on sufficient/insufficient response, and predictors of insufficient response, to acute treatments for migraine are limited in Japan. This study aimed to identify factors associated with insufficient response to acute treatment of migraine by exploring significant differences between people with migraine who sufficiently/insufficiently respond to prescribed acute treatment in Japan.
METHODS
METHODS
This was a retrospective analysis of 2014 Adelphi Migraine Disease Specific Programme cross-sectional survey data collected from physicians and their consulting adult patients with migraine in Japan. Insufficient responders to prescribed acute treatment were patients who achieved headache pain freedom within 2 h of acute treatment in no more than three of their last five migraine attacks. Factors associated with insufficient response to prescribed acute migraine treatment were identified using backward logistic regression.
RESULTS
RESULTS
Overall, 227/538 (42.2%) patients were classified as insufficient responders to prescribed acute migraine treatment. Significantly more insufficient responders than sufficient responders had consulted a neurologist or a migraine/headache specialist, and had chronic migraine or medication-overuse or tension-type headaches (p < 0.05). More insufficient responders than sufficient responders reported taking acute treatment when/after the pain started (77.0 vs. 68.9%) than at first sign of migraine (p < 0.05). Compared with sufficient responders, insufficient responders reported a significantly higher mean ± standard deviation (SD) Migraine Disability Assessment total score (12.7 ± 23.3 vs. 5.8 ± 10.4, p < 0.001) and lower quality of life (EuroQol-5 Dimensions utility score 0.847 ± 0.19 vs. 0.883 ± 0.16, p = 0.024). Factors significantly associated with insufficient response to acute treatment included seeing a neurologist versus an internist (odds ratio [OR] 1.93; 95% confidence interval [CI] 1.29-2.88; p = 0.002), taking acute medication when/after pain started versus at first sign of migraine (OR 1.65; 95% CI 1.05-2.60; p = 0.030), a higher MIDAS total score (OR 1.04; 95% CI 1.02-1.06; p < 0.001), and presence of comorbid cardiovascular disease (OR 0.53; 95% CI 0.28-0.98; p = 0.044).
CONCLUSIONS
CONCLUSIONS
Many people with migraine in Japan struggle to adequately treat migraine attacks with prescribed acute medication and exhibit high levels of unmet need for acute treatment. Optimized management strategies utilizing existing therapeutic options as well as additional effective therapeutic options for migraine are required to improve symptoms and quality of life.
Identifiants
pubmed: 32641075
doi: 10.1186/s12883-020-01848-4
pii: 10.1186/s12883-020-01848-4
pmc: PMC7341635
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
274Subventions
Organisme : Eli Lilly and Company
ID : N/A
Références
Headache. 2011 Jan;51(1):64-72
pubmed: 21054362
Curr Pain Headache Rep. 2012 Feb;16(1):86-92
pubmed: 22083262
Headache. 2015 Apr;55(4):502-18
pubmed: 25881676
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Am Fam Physician. 2011 Feb 1;83(3):271-80
pubmed: 21302868
J Headache Pain. 2019 Jun 7;20(1):68
pubmed: 31174464
Headache. 2005 Feb;45(2):156-62
pubmed: 15705122
Neurology. 2015 Feb 17;84(7):688-95
pubmed: 25609757
Cephalalgia. 2013 Aug;33(11):891-6
pubmed: 23564209
Cephalalgia. 2008 Jan;28(1):35-40
pubmed: 17941878
Neurology. 2001;56(6 Suppl 1):S20-8
pubmed: 11294956
Qual Life Res. 2016 Mar;25(3):707-19
pubmed: 26303761
Headache. 2007 Apr;47(4):519-30
pubmed: 17445101
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Headache. 2013 Sep;53(8):1300-11
pubmed: 23879870
Cephalalgia. 2019 Oct;39(12):1518-1534
pubmed: 31154807
Cephalalgia. 2019 May;39(6):687-710
pubmed: 30806518
Cephalalgia. 2010 Jul;30(7):838-46
pubmed: 20647175
Headache. 2015 Jul-Aug;55 Suppl 4:221-35
pubmed: 26178694
Cephalalgia. 2011 Feb;31(3):301-15
pubmed: 20813784
J Headache Pain. 2019 Apr 2;20(1):31
pubmed: 30940092
Curr Med Res Opin. 2008 Nov;24(11):3063-72
pubmed: 18826746
Headache. 2017 Jul;57(7):1026-1040
pubmed: 28603893
J Headache Pain. 2020 Apr 29;21(1):41
pubmed: 32349662
J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):428-32
pubmed: 20164501
J Neurol Sci. 2017 Jan 15;372:307-315
pubmed: 28017235
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Cephalalgia. 1999 Mar;19(2):107-14; discussion 74
pubmed: 10214536
Headache. 2002 Jan;42 Suppl 1:3-9
pubmed: 11966858
Headache. 2008 Feb;48(2):184-93
pubmed: 18234045
Headache. 2020 Jun 8;:
pubmed: 32510611
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Cephalalgia. 2014 Apr;34(5):376-81
pubmed: 24265285
Headache. 2016 Nov;56(10):1635-1648
pubmed: 27731896
Neurology. 2004 Aug 10;63(3):520-4
pubmed: 15304585